{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:57:18Z","timestamp":1777888638924,"version":"3.51.4"},"reference-count":50,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2023,3,13]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nausea is common upon initiating dopamine agonists in patients with Parkinson\u2019s disease (PD); however, pretreatment with an antiemetic is recommended only when initiating apomorphine formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Evaluate the need for prophylactic antiemetic use during dose optimization of apomorphine sublingual film (SL-APO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A post hoc analysis of a Phase III study evaluated nausea and vomiting treatment-emergent adverse events in patients with PD who underwent SL-APO dose optimization (10\u201335\u200amg; 5-mg increments) to achieve a tolerable FULL ON. Frequencies of nausea and vomiting were described for patients who did versus did not use an antiemetic during dose optimization and by patient subgroups based on extrinsic and intrinsic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 43.7% (196\/449) of patients did not use an antiemetic during dose optimization; most of these patients (86.2% [169\/196]) achieved an effective and tolerable SL-APO dose. In patients who did not use an antiemetic, nausea (12.2% [ 24\/196 ]) and vomiting (0.5% [ 1\/196 ]) were uncommon. An antiemetic was used in 56.3% (253\/449) of patients, with 17.0% (43\/253) and 2.4% (6\/253) experiencing nausea and vomiting, respectively. All events of nausea (14.9% [67\/449]) and vomiting (1.6% [ 7\/449 ]) were of mild-to-moderate severity except for 1 event each. Irrespective of antiemetic use, among patients without baseline dopamine agonist use, nausea and vomiting rates were 25.2% (40\/159) and 3.8% (6\/159); in those already using dopamine agonists, rates were 9.3% (27\/290) and 0.3% (1\/290).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Prophylactic treatment with an antiemetic is not necessary for most patients who initiate SL-APO for the treatment of OFF episodes in PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jpd-223537","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T12:37:13Z","timestamp":1679661433000},"page":"403-414","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson\u2019s Disease: Is the Prophylactic Use of an Antiemetic Necessary?"],"prefix":"10.1177","volume":"13","author":[{"given":"Robert A.","family":"Hauser","sequence":"first","affiliation":[{"name":"University of South Florida, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[{"name":"Methodist Neurological Institute, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc., Marlborough, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Bowling","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc., Marlborough, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford","family":"Navia","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc., Marlborough, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pappert","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc., Marlborough, MA, USA"},{"name":"Neurology Associates, San Antonio, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[{"name":"University of South Florida, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the CTH-301 Study Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26731"},{"key":"ref002","first-page":"6762528","volume":"2016","author":"Poirier AA","year":"2016","journal-title":"Parkinsons Dis"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22360"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a1d44c"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105124"},{"key":"ref006","unstructured":"REQUIP\u00ae (ropinirole hydrochloride) (2007) Glaxo Smith Kline. Research Triangle Park, NC, USA."},{"key":"ref007","unstructured":"MIRAPEX ER\u00ae  (pramipexole dihydrochloride) extended release tablets (2014) Boehringer Ingelheim International GmbH."},{"key":"ref008","unstructured":"REQUIP XL (ropinirole) extended-release tablets (2018) GlaxoSmithKline: Research Triangle Park, NC, USA."},{"key":"ref009","unstructured":"NEUPRO\u00ae (rotigotine transdermal system) (2020) UCB, Inc., Smyrna, GA, USA."},{"key":"ref010","unstructured":"MIRAPEX\u00ae (pramipexole dihydrochloride) tablets (2020) Boehringer Ingelheim International GmbH."},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.9.1385"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26697"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31816d91f9"},{"key":"ref014","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.6.681"},{"key":"ref015","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2006.06.012"},{"key":"ref016","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.65.5.709"},{"key":"ref017","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30396-5"},{"key":"ref018","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.12.024"},{"key":"ref019","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00194-7"},{"key":"ref020","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28926"},{"key":"ref021","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550020057038"},{"key":"ref022","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.5.676"},{"key":"ref023","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1057"},{"key":"ref024","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000258660.74391.c1"},{"key":"ref025","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.12.1721"},{"key":"ref026","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.4.436"},{"key":"ref027","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199619030-00005"},{"key":"ref028","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.02.014"},{"key":"ref029","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100108"},{"key":"ref030","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30239-4"},{"key":"ref031","unstructured":"APO-go Pen\u00ae SoPC (2018) Britannia Pharmaceuticals Limited. Berkshire, UK."},{"key":"ref032","unstructured":"APOKYN\u00ae (apomorphine hydrochloride injection) (2020) US World Meds, LLC, Louisville, KY, USA."},{"key":"ref033","unstructured":"KYNMOBI\u00ae (apomorphine hydrochloride) sublingual film (2020) Sunovion Pharmaceuticals Inc., Marlborough, MA, USA."},{"key":"ref034","unstructured":"US Food and Drug Administration (2020) FDA Drug Shortages, US Food and Drug Administration, Silver Spring, MD."},{"key":"ref035","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.11.017"},{"key":"ref036","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.04.008"},{"key":"ref037","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.08.010"},{"key":"ref038","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.01.001"},{"key":"ref039","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.10.025"},{"key":"ref040","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12350"},{"key":"ref041","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03920-5"},{"key":"ref042","unstructured":"TIGAN\u00ae (trimethobenzamide hydrochloride) (2007) King Pharmaceuticals Inc., Briston, TN, USA."},{"key":"ref043","unstructured":"Domperidone Summary of Product Characteristics (2021), Aurobindo Pharma - Milpharm Ltd. South Ruislip, UK."},{"key":"ref044","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01197"},{"key":"ref045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1994.tb03576.x"},{"key":"ref046","doi-asserted-by":"publisher","DOI":"10.1080\/22201173.2007.10872495"},{"key":"ref047","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2011.620193"},{"key":"ref048","unstructured":"Center for Drug Evaluation and Research (2004) Clinical NDA review of sponsor,s response to approval letter for APOKYN (apomorphine). NDA Number 21264."},{"key":"ref049","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199110000-00009"},{"key":"ref050","first-page":"967","volume":"80","author":"Hvarfner A","year":"1995","journal-title":"Anesth Analg"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-223537","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JPD-223537","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-223537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:52:22Z","timestamp":1777611142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JPD-223537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,13]]}},"alternative-id":["10.3233\/JPD-223537"],"URL":"https:\/\/doi.org\/10.3233\/jpd-223537","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]}}}